The reduced duration of SIRS and bodyweight loss in the ghrelin therapy group found in the current study and the studies by others is likely due to replacement of ghrelin which is inevitably decreased following oesophagectomy due to decrease in endogenous production of plasma ghrelin [20]. This evidence concerns the gene GHRL and systemic inflammatory response syndrome.